SCHEMBL23364352

SCHEMBL23364352

CN(C)c1ccc(-c2ccc(-c3nc4ccc(NCCOCCOCCOCCOCCOCCOc5ccc6c(c5)CN(C5CCC(=O)NC5=O)C6=O)cc4s3)cc2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 1.00
SNCA P37840 1/20 0.50
CRBN Q96SW2 2/20 0.46
IKZF2 Q9UKS7 7/20 0.40
WIZ O95785 2/20 0.39
DDB1 Q16531 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23364377 1.00 MAPT (1.00) MAPTSNCACRBNIKZF2WIZ
SCHEMBL23386223 1.00 MAPT (1.00) MAPTSNCACRBNIKZF2WIZ
SCHEMBL29874445 1.00 MAPT (1.00) MAPTSNCACRBNIKZF2WIZ
SCHEMBL29453220 1.00 MAPT (1.00) MAPTSNCACRBNIKZF2WIZ
SCHEMBL23386252 0.95 MAPT (0.91) MAPTSNCACRBNIKZF2WIZ
SCHEMBL23386254 0.95 MAPT (0.91) MAPTSNCACRBNIKZF2WIZ
SCHEMBL26513433 0.95 MAPT (0.90) MAPTSNCACRBNIKZF2WIZ
SCHEMBL23386215 0.93 MAPT (0.87) MAPTSNCAIKZF2WIZ
SCHEMBL26514012 0.93 MAPT (0.87) MAPTSNCACRBNIKZF2WIZ
SCHEMBL23386225 0.93 MAPT (0.86) MAPTSNCACRBNIKZF2WIZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4337259-A1 COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF Aprinoia Therapeutics Limited (HK) 2024-03-20 EP disclosed
US-20230346955-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-02 US disclosed
US-20230346955-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-02 US disclosed
US-11642413-B2 Compounds for degrading Tau protein aggregates and uses thereof APRINOIA THERAPEUTICS LIMITED (CN) 2023-05-09 US disclosed
US-11642413-B2 Compounds for degrading Tau protein aggregates and uses thereof APRINOIA THERAPEUTICS LIMITED (CN) 2023-05-09 US disclosed
US-20220354835-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2022-11-10 US disclosed
US-20220267316-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2022-08-25 US disclosed
WO-2021097243-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2021-05-20 WO disclosed
WO-2021097243-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267316-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF MAPT, PRNP, APP MAPT 1/4885SNCA 36/4885CRBN 1080/4885
US-20230346955-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF MAPT, PRNP, APP MAPT 1/4885SNCA 36/4885CRBN 1080/4885
US-11642413-B2 Compounds for degrading Tau protein aggregates and uses thereof MAPT, PRNP, APP MAPT 1/4885SNCA 36/4885CRBN 1080/4885
US-20220354835-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF MAPT, PRNP, APP MAPT 1/4885SNCA 43/4885CRBN 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.